Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dynavax Technologies Corporation
Age
50–69
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female, 50 to 69 years of age
Be in good health in the opinion of the investigator, based upon medical history, physical examination, and laboratory evaluation
Must be able to comprehend and follow all required study procedures and be available for all visits scheduled in the study
Seronegative for human immunodeficiency virus (HIV)
You may not be if
History of HZ
Previous vaccination against varicella or HZ
If female of childbearing potential, is pregnant, breastfeeding, or planning a pregnancy
Known history of HIV (HIV 1/2 antibodies)
Has a history of sensitivity to any component of study vaccines
Has received any blood products or immunoglobulin within 90 days prior to study injection, or is likely to require infusion of blood products during the study period
Has received the following prior to the first injection:
* 14 days: any non-live vaccine
* 28 days:
* Any live vaccine, including a COVID-19 vaccine
* Systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication, with the exception of inhaled steroids
* Granulocyte or granulocyte-macrophage colony-stimulating factor
* Any other investigational medicinal agent, including a COVID-19 vaccine
Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose
Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous cell or basal cell carcinoma of the skin
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator